Ørsted New Bio Solutions Holding A/S — Financial report

CVR 32319017

Latest financial period

  • 2025 • 2025-01-01 • 2025-12-31 • entity • DKK • -14000 • -14000 • -500070000 • 116433000 • 116410000 • 1000

Financial history

  • 2024 • 2024-01-01 • 2024-12-31 • entity • DKK • -11000 • -11000 • -11775000 • 46824000 • 46480000 • 1000
  • 2023 • 2023-01-01 • 2023-12-31 • entity • DKK • -16000 • -16000 • -193796000 • 58610000 • 58255000 • 1000
  • 2022 • 2022-01-01 • 2022-12-31 • entity • DKK • 0 • -12000 • -12000 • 121000 • 252096000 • 252051000 • 1
  • 2021 • 2021-01-01 • 2021-12-31 • entity • DKK • 1000 • -27000 • -27000 • -10371000 • 78441000 • 78428000 • 1
  • 2020 • 2020-01-01 • 2020-12-31 • entity • DKK • 0 • -13000 • -13000 • -12858000 • 88824000 • 88799000 • 1
  • 2019 • 2019-01-01 • 2019-12-31 • entity • DKK • -27000 • -17719000 • 121668000 • 121657000
  • 2018 • 2018-01-01 • 2018-12-31 • entity • DKK • 3000 • -32069000 • 139387000 • 139376000

Annual report highlights

  • primary activities • The purpose of establishing the Company is to conduct business within the environmental and energy sector including related activities, research and advisory.Orsted New Bio Solutions Holding A/S has 3 subsidaries in Denmark.On 16 December 2024, Renescience A/S (the subsidiaty of the Company) entered into a Share Purchase Agreement for the sale of its subsidiaries, Ørsted Renescience Northwich Ltd. and Ørsted Renescience Northwich O&M Ltd. The transaction was completed on 31 October 2025. A key term of the agreement required the subsidiaries to be sold on a debt-free basis. To satisfy this condition, Ørsted New Bio Solutions Holding A/S made an additional capital contribution to Renescience A/S prior to closing. Consequently, a significant impairment was recognised on this investment to reflect the impact of the transaction in the Annual Report. • entity
  • primary activities • The purpose of establishing the Company is to conduct business within the environmental and energy sector including related activities, research and advisory. Orsted New Bio Solutions Holding A/S has 3 subsidaries in Denmark. On 16 December 2024, Renescience A/S (the subsidiaty of the Company) entered into a Share Purchase Agreement for the sale of its subsidiaries, Ørsted Renescience Northwich Ltd. and Ørsted Renescience Northwich O&M Ltd. The transaction was completed on 31 October 2025. A key term of the agreement required the subsidiaries to be sold on a debt-free basis. To satisfy this condition, Ørsted New Bio Solutions Holding A/S made an additional capital contribution to Renescience A/S prior to closing. Consequently, a significant impairment was recognised on this investment to reflect the impact of the transaction in the Annual Report. • entity
  • contingent liabilities • The group's Danish companies are jointly and severally liable for tax on group jointly taxes income, etc. Reference is made to the annual report for Ørsted A/S, the administration company in relation to joint taxation. The group's Danish companies are also jointly and severally liable for Danish withholding taxes on dividends, royalties and interests within the group of jointly taxed entities. Any subsequent corrections to income and withholding taxes may result in an increase in the entities' liability. The group's danish entities are jointly and severally liable for joint VAT registration. • entity